Therapy of small cell lung cancer with emphasis on oral
topotecan

J 2010

Therapy of small cell lung cancer with emphasis on oral topotecan

PIRKER, Robert; Peter BERZINEC; S. BRINCAT; P. KASAN; G. OSTOROS et al.

Základní údaje

Originální název

Therapy of small cell lung cancer with emphasis on oral topotecan

Autoři

Vydání

Lung Cancer, 2010, 0169-5002

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Irsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 3.356

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/10:00051508

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1016/j.lungcan.2010.05.020

UT WoS

000282503700002

Klíčová slova anglicky

Chemotherapy; New drugs; Thoracic radiotherapy; Brain irradiation; Second-line therapy; Topotecan

Příznaky

Mezinárodní význam

Změněno: 16. 4. 2012 13:29, Mgr. Michal Petr

Anotace

V originále

Systemic chemotherapy plays the major role in the management of patients with small cell lung cancer. Cisplatin plus etoposide is the most widely used regimen and is considered as standard in patients with limited disease. Cisplatin plus irinotecan improved survival compared to cisplatin plus etoposide in a Japanese trial but failed to do so in two trials in Caucasians. Cisplatin plus topotecan had similar efficacy compared to cisplatin plus etoposide in patients with extensive disease. In the second-line setting, topotecan showed similar efficacy but better tolerability compared to cyclophosphamide, doxorubin plus vincristine. Oral topotecan was as efficacious as its intravenous formulation and was shown to improve survival compared to best supportive care alone in patients previously treated with chemotherapy. Thus topotecan is considered as the standard second-line chemotherapy in patients with small cell lung cancer.

Citovat

PIRKER, Robert; Peter BERZINEC; S. BRINCAT; P. KASAN; G. OSTOROS; M. PESEK; S. PLATE; G. PURKALNE; R. ROONEEM; Jana SKŘIČKOVÁ; D. STANCULEANU; C. TIMCHEVA; V. TZEKOVA; B. ZAKOTNIK; Ch.C. ZIELINSKI a M. ZWITTER. Therapy of small cell lung cancer with emphasis on oral topotecan. Lung Cancer. 2010, roč. 70, č. 1, s. 7-13. ISSN 0169-5002. Dostupné z: https://doi.org/10.1016/j.lungcan.2010.05.020.

@article{906668,
   author = {Pirker, Robert and Berzinec, Peter and Brincat, S. and Kasan, P. and Ostoros, G. and Pesek, M. and Plate, S. and Purkalne, G. and Rooneem, R. and Skřičková, Jana and Stanculeanu, D. and Timcheva, C. and Tzekova, V. and Zakotnik, B. and Zielinski, Ch.C. and Zwitter, M.},
   article_number = {1},
   doi = {https://doi.org/10.1016/j.lungcan.2010.05.020},
   keywords = {Chemotherapy; New drugs; Thoracic radiotherapy; Brain irradiation; Second-line therapy; Topotecan},
   language = {eng},
   issn = {0169-5002},
   journal = {Lung Cancer},
   title = {Therapy of small cell lung cancer with emphasis on oral topotecan},
   volume = {70},
   year = {2010}
}

TY  - JOUR
ID  - 906668
AU  - Pirker, Robert - Berzinec, Peter - Brincat, S. - Kasan, P. - Ostoros, G. - Pesek, M. - Plate, S. - Purkalne, G. - Rooneem, R. - Skřičková, Jana - Stanculeanu, D. - Timcheva, C. - Tzekova, V. - Zakotnik, B. - Zielinski, Ch.C. - Zwitter, M.
PY  - 2010
TI  - Therapy of small cell lung cancer with emphasis on oral topotecan
JF  - Lung Cancer
VL  - 70
IS  - 1
SP  - 7-13
EP  - 7-13
SN  - 01695002
KW  - Chemotherapy
KW  - New drugs
KW  - Thoracic radiotherapy
KW  - Brain irradiation
KW  - Second-line therapy
KW  - Topotecan
N2  - Systemic chemotherapy plays the major role in the management of patients with small cell lung cancer. Cisplatin plus etoposide is the most widely used regimen and is considered as standard in patients with limited disease. Cisplatin plus irinotecan improved survival compared to cisplatin plus etoposide in a Japanese trial but failed to do so in two trials in Caucasians. Cisplatin plus topotecan had similar efficacy compared to cisplatin plus etoposide in patients with extensive disease. In the second-line setting, topotecan showed similar efficacy but better tolerability compared to cyclophosphamide, doxorubin plus vincristine. Oral topotecan was as efficacious as its intravenous formulation and was shown to improve survival compared to best supportive care alone in patients previously treated with chemotherapy. Thus topotecan is considered as the standard second-line chemotherapy in patients with small cell lung cancer.
ER  -

PIRKER, Robert; Peter BERZINEC; S. BRINCAT; P. KASAN; G. OSTOROS; M. PESEK; S. PLATE; G. PURKALNE; R. ROONEEM; Jana SKŘIČKOVÁ; D. STANCULEANU; C. TIMCHEVA; V. TZEKOVA; B. ZAKOTNIK; Ch.C. ZIELINSKI a M. ZWITTER. Therapy of small cell lung cancer with emphasis on oral topotecan. \textit{Lung Cancer}. 2010, roč.~70, č.~1, s.~7-13. ISSN~0169-5002. Dostupné z: https://doi.org/10.1016/j.lungcan.2010.05.020.

Přehled o publikaci